Bio-Rad Laboratories, Inc. Reports Second-Quarter Currency-Neutral Revenue Growth of 9 Percent

HERCULES, CA--(Marketwire - August 03, 2010) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the second quarter ended June 30, 2010.

Second-quarter reported revenues were $467.7 million, up 9.5% compared to $427.2 million reported for the second quarter of 2009. On a currency-neutral basis, quarterly revenues increased 9.0% compared to the same period last year. This improvement is the result of organic growth across Bio-Rad’s two main areas, Life Science and Clinical Diagnostics, as well as revenue of $14.5 million resulting from the addition of certain diagnostics businesses of Biotest AG to the Company’s portfolio in the first quarter of 2010. Excluding the revenue from the Biotest acquisition, second-quarter revenues were up 6.1% or 5.5% on a currency neutral basis, compared to the same period last year. Second-quarter gross margin increased to 57.4% primarily due to benefits of certain unique items. Excluding these items, second-quarter gross margin would have been 56.4% compared to 56.6% reported during the same quarter last year.

Net income attributable to Bio-Rad for the second quarter of 2010 was unchanged at $38.0 million compared to the second quarter in 2009. Second-quarter earnings were $1.35 per share on a fully diluted basis versus $1.37 per share reported for the same period last year.

Year-to-date revenues grew by 11.3% to $921.9 million compared to the first two quarters in 2009. Adjusting for the impact of currency, revenue growth was 8.4%. Excluding the additional revenue from the Biotest acquisition, year-to-date organic revenues grew by 8.0% to $894.7 million, or 5.2% on a currency-neutral basis.

Year-to-date net income attributable to Bio-Rad at June 30, 2010 was $72.8 million, or $2.59 per share on a fully diluted basis, compared to $68.2 million, or $2.47 per share, respectively, during the same period in 2009.

“We are pleased with our performance for the first half of the year, which reflects strength in our core product lines as well as favorable customer acceptance of products introduced this year,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “While our customers’ budgets in parts of the world continue to be constrained, the outlook for the year remains positive.”

Life Science

The Life Science segment net sales for the second quarter were $150.7 million, up 0.6% compared to the same period last year. On a currency-neutral basis, Life Science segment sales decreased by 0.1% compared to the second quarter of 2009. Sales of certain core product lines performed well during the quarter, in particular, the recently introduced TC10™ automated cell counter, which provides a simple, rapid, and reproducible alternative to researchers who count cells. Performance of the segment benefited from the Company’s next generation PCR instruments, most notably, the CFX96™ real-time PCR detection system and associated reagents. Bio-Rad’s Mini-PROTEAN® TGX™ precast electrophoresis gel product line, which offers high resolution and fast time to results, also performed well and is rapidly gaining customer acceptance.

Clinical Diagnostics

Reported net sales for the Clinical Diagnostics segment in the second quarter rose to $314.1 million, up 14.5% compared to the same quarter last year. On a currency-neutral basis, net sales were up 14.1%. Excluding revenue from the Biotest acquisition, net sales were up 9.2%, or 8.7% on a currency-neutral basis compared to the same period last year. These gains were the result of growth across all product lines most notably quality controls, blood typing, and diabetes monitoring, as well as additional revenue from new diagnostics businesses of Biotest AG that were added to the Company’s portfolio in the first quarter. During the second quarter, Bio-Rad announced the launch of its IH-1000 blood typing system for markets outside the U.S. The instrument is a fully-automated, high-throughput system designed for the blood transfusion laboratory. Also during the second quarter, the Company launched the BioPlex® 2200 MMRV IgG kit for use on the Company’s BioPlex® 2200 system. The MMRV IgG kit (measles; mumps; rubella; and the varicella-zoster virus, commonly known as chicken pox) provides simultaneous results for the four tests that are typically ordered together to determine a patient’s susceptibility to MMRV.

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) August 3, 2010. Interested parties may access the call by dialing 800-901-5259 (in the U.S.) or 617-786-4514 (international), access number 36675924.

A live webcast of the conference call may be accessed in the “Investor Relations” section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 81420296, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the “Investor Relations” section of www.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

 Bio-Rad Laboratories, Inc. Condensed Consolidated Statements of Income (in thousands, except per share data) (UNAUDITED) Three Months Ended Six Months Ended June 30, June 30, -------------------- -------------------- 2010 2009 2010 2009 --------- --------- --------- --------- Net sales $ 467,662 $ 427,183 $ 921,896 $ 828,116 Cost of goods sold 199,354 185,221 396,461 357,253 --------- --------- --------- --------- Gross profit 268,308 241,962 525,435 470,863 Selling, general and administrative expense 156,270 143,670 309,887 283,983 Research and development expense 43,862 42,407 84,125 79,558 --------- --------- --------- --------- Income from operations 68,176 55,885 131,423 107,322 Interest expense 14,325 10,367 28,769 18,174 Foreign exchange losses, net 1,014 2,551 797 1,777 Other income, net (2,517) (6,307) (3,316) (5,148) --------- --------- --------- --------- Income before taxes 55,354 49,274 105,173 92,519 Provision for income taxes (16,833) (9,974) (31,260) (21,176) --------- --------- --------- --------- Net income including noncontrolling interests 38,521 39,300 73,913 71,343 Less: Net income attributable to noncontrolling interests (564) (1,331) (1,095) (3,109) --------- --------- --------- --------- Net income attributable to Bio-Rad $ 37,957 $ 37,969 $ 72,818 $ 68,234 ========= ========= ========= ========= Basic earnings per share: Net income per share basic attributable to Bio-Rad $ 1.37 $ 1.39 $ 2.64 $ 2.50 ========= ========= ========= ========= Weighted average common shares - basic 27,606 27,370 27,575 27,346 ========= ========= ========= ========= Diluted earnings per share: Net income per share diluted attributable to Bio-Rad $ 1.35 $ 1.37 $ 2.59 $ 2.47 ========= ========= ========= ========= Weighted average common shares - diluted 28,125 27,742 28,097 27,681 ========= ========= ========= ========= Bio-Rad Laboratories, Inc. Condensed Consolidated Balance Sheets (In thousands) (UNAUDITED) June 30, December 31, 2010 2009 ------------ ------------ Current assets: Cash and cash equivalents $ 614,223 $ 649,938 Short-term investments 103,486 94,876 Accounts receivable, net 335,354 345,734 Inventories, net 370,272 351,206 Other current assets 132,492 120,920 ------------ ------------ Total current assets 1,555,827 1,562,674 Property, plant and equipment, net 305,936 302,417 Goodwill, net 329,386 327,626 Purchased intangibles, net 199,922 204,779 Other assets 136,053 138,357 ------------ ------------ Total assets $ 2,527,124 $ 2,535,853 ============ ============ Current liabilities: Accounts payable $ 95,161 $ 92,988 Accrued payroll and employee benefits 111,518 126,702 Notes payable and current maturities of long-term debt 9,750 5,132 Income and other taxes payable 44,003 42,322 Other current liabilities 129,063 152,828 ------------ ------------ Total current liabilities 389,495 419,972 Long-term debt, net of current maturities 734,339 737,919 Other long-term liabilities 100,558 98,749 ------------ ------------ Total liabilities 1,224,392 1,256,640 Bio-Rad stockholders’ equity 1,285,131 1,259,726 Noncontrolling interests 17,601 19,487 ------------ ------------ Total stockholders’ equity 1,302,732 1,279,213 ------------ ------------ Total liabilities and stockholders’ equity $ 2,527,124 $ 2,535,853 ============ ============ Bio-Rad Laboratories, Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (UNAUDITED) Six Months Ended June 30, 2010 2009 --------- --------- Cash flows from operating activities: Cash received from customers $ 891,658 $ 831,208 Cash paid to suppliers and employees (779,464) (698,527) Interest paid (27,861) (15,340) Income tax payments (28,169) (13,220) Other operating activities 2,491 7,742 --------- --------- Net cash provided by operating activities 58,655 111,863 Cash flows from investing activities: Payments for acquisitions and long-term investments (67,345) (33,805) Other investing activities (35,804) (36,965) --------- --------- Net cash used in investing activities (103,149) (70,770) Cash flows from financing activities: Payments on long-term debt (2,940) (3,585) Other financing activities 7,131 294,690 --------- --------- Net cash provided by financing activities 4,191 291,105 Effect of foreign exchange rate changes on cash 4,588 (3,248) --------- --------- Net increase (decrease) in cash and cash equivalents (35,715) 328,950 Cash and cash equivalents at beginning of period 649,938 204,524 --------- --------- Cash and cash equivalents at end of period $ 614,223 $ 533,474 ========= ========= Reconciliation of net income including noncontrolling interests to net cash provided by operating activities: Net income including noncontrolling interests $ 73,913 $ 71,343 Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities: Depreciation and amortization 53,633 47,765 Changes in working capital (53,028) (7,490) Other (15,863) 245 --------- --------- Net cash provided by operating activities $ 58,655 $ 111,863 ========= =========